Novel method for reducing plasma cholesterol: a ligand replacement therapy

References

• Virchow, Rudolf. “Gesammelte Abhandlungen zur wissenschaftlichen Medizin”. Vierteljahrschrift für die praktische Heilkunde (Germany: Staatsdruckerei Frankfurt). Phlogose und Thrombose im Gefäßsystem (1856).
   Google Scholar
• Anitschkow NN, Chatalov S. Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse. Zentralbl. Allg. Pathol. 24, 1–9 (1913).
   Google Scholar
• Ahrens EH Jr. The management of hyperlipidemia: whether, rather than how. Ann. Intern. Med. 85, 87–93 (1976).
   Google Scholar
• Rifkind, BM. The Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Am. J. Cardiol. 54, C30–C34 (1984).
   Google Scholar
• From NIH Consensus Development Conference. JAMA 253, 2080 (1985).
   Google Scholar
• Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986).
   Google Scholar
• Brown MS, Goldstein JL. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 6, 307–l6 (1975). •• This is the first demonstration of receptor-mediated clearance of LDL.
   Google Scholar
• Yokoyama C. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75, 187–197 (1993).
   Google Scholar
• Endo, A. The Discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569–1580 (1992). •• This discovery marks the beginning of agents to lower plasma cholesterol levels.
   Google Scholar
• Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36–46 (2010).
   Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366, 1267–1278 (2005).
   Google Scholar
• Steinberg DS, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hyperlipidemia. Circulation 118, 672–677 (2008).
   Google Scholar
• Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: prospective meta-analysis of data from 170,000 participants in 26 randomized trials of statins. Lancet 376, 1670–1381 (2010).
   Google Scholar
• Davidson M. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr. Atheroscler. Rep. 11, 67–70 (2009).
   Google Scholar
• Khera AV, Rader DJ. Future therapeutic directions in reverse cholesterol transport. Curr. Atheroscler. Rep. 12, 73–81 (2010).
   Google Scholar
• Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat. Rev. Cardiol. 8, 253–265 (2011).
   Google Scholar
• Vickers KC, Remaley AT. HDL and cholesterol: life after the divorce? J. Lipid Res. 55, 4–12 (2014).
   Google Scholar
• Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study. Lancet 380, 572–580 (2012).
   Google Scholar
• Varbo A, Benn M, Tybjærg-Hansen A et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 61, 427–436 (2013).
   Google Scholar
• Visser ME, Wagener G, Baker BF et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur. Heart J. 33, 1142–1149 (2012).
   Google Scholar
• Cuchel M, Meagher EA, du Toit Theron H et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, Phase 3 study. Lancet 381, 40–46 (2013).
   Google Scholar
• Feingold KR. Does inhibition of apoliprotein B synthesis produce foie gras? J. Lipid Res. 51, 877–878 (2010).
   Google Scholar
• Raal FJ. Lomitapide for homozygous familial hypercholesterolemia. Lancet 381, 7–8 (2013).
   Google Scholar
• Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J. Intern. Med. 10. 1365–2796 (2009).
   Google Scholar
• Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50, S172–S177 (2009).
   Google Scholar
• Duff CJ, Scott MJ, Kirby IT et al. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem. J. 419, 577–584 (2009).
   Google Scholar
• Lambert G, Sjouke B, Choque B et al. The PCSK9 decade. J. Lipid Res. 53, 2515–2524 (2012).
   Google Scholar
• Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105, 11915–11920 (2008).
   Google Scholar
• Stock J. Improving the care of high-risk patients: the potential of PCSK9. Atherosclerosis 232, 420–422 (2014).
   Google Scholar
• Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40, 1–16 (1999).
   Google Scholar
• White CR, Garber DW, Anantharamaiah GM. Anti-inflammatory and. cholesterol-reducing properties of apolipoprotein mimetics: a review. J. Lipid Res. 55, 2007–2021 (2014).
   Google Scholar
• Sergio Fazio, Zemin Yao. The Enhanced Association of Apolipoprotein E With Apolipoprotein B–Containing Lipoproteins in Serum-Stimulated Hepatocytes Occurs Intracellularly. Arterio. Thromb. Vasc. Biol. 15, 593–600 (1995).
   Google Scholar
• Christianson HC, Belting M. Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol. 35, 51–55 (2014).
   Google Scholar
• MacArthur JM, Bishop JR, Stanford KI et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 117, 153–164 (2007).
   Google Scholar
• Stanford KI, Bishop JR, Foley EM et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J. Clin. Invest. 119, 3236–3245 (2009).
   Google Scholar
• Chen K, Williams KJ. Molecular mediators for raftdependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor. J. Biol. Chem. 288(20), 13988–13999 (2013).
   Google Scholar
• Mahley, RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622–630 (1988).
   Google Scholar
• Mahley RW, Weisgraber KH, Hussain MM et al. Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits J. Clin. Invest. 83, 2125–2130 (1989).
   Google Scholar
• Linton, MF. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 267, 1034–1037 (1995).
   Google Scholar
• Weisgraber, K. H. Apolipoprotein E: structure–function relationships. Adv. Protein Chem. 45, 249–302 (1994).
   Google Scholar
• Datta G, Chaddha M, Garber D W et al. (2000). The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by firbroblasts. Biochemistry 39, 213–220.
   Google Scholar
• Anantharamaiah GM, Mishra VK, Garber DW et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48, 1915–1923 (2007).
   Google Scholar
• Datta G, Garber DW, Chung BH et al. Cationic domain 141–150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J. Lipid Res. 42(6), 959–966 (2001).
   Google Scholar
• Gupta H, White R, Handattu S et al. Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe Heritable Hyperlipidemic Rabbits. Circulation 111, 3112–3118 (2005).
   Google Scholar
• Garber DW, Handattu S, Aslan I et al. Effect of an argininerich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 168(2), 229–237 (2003) (2003).
   Google Scholar
• Ali K, Middleton M, Pure E, Rader DI. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ. Res. 97, 922–927 (2005).
   Google Scholar
• Van Oosten M, Rense PCN, Amersfoort ESV et al. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. J. Biol. Chem. 276, 8820–8824 (2001).
   Google Scholar
• de Bont N, Demaker K, Meer VD et al. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur. J. Clin. Invest. 30, 818–822 (2000).
   Google Scholar
• Levine DM, Parker TS, Donelle, TM et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl Acad. Sci. USA 90, 12040–12044 (1993).
   Google Scholar
• Wang, H, Christensen DJ, Vitek MP et al. APOE genotype affects outcome in a murine model of sepsis: implications for a new treatment strategy. Anaesth. Intensive Care 37, 38–45 (2009).
   Google Scholar
• Moretti EW, Morris RW, Podgoreanu M et al. APOE polymorphism is associated with risk of severe sepsis in surgical patients. Crit. Care Med. 33, 2521–2526 (2005).
   Google Scholar
• Roselaar SE, Daugherty A. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J. Lipid Res. 39, 1740–1743 (1998).
   Google Scholar
• Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Aterioscler. Thromb. Vasc. Biol. 25, 436–441 (2005).
   Google Scholar
• Gaudreault N, Kumar N, Posada JM et al. Apo E suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 32, 264–272 (2012).
   Google Scholar
• Handattu SP, Nayyar G, Garber DW et al. Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis 227, 58–64 (2013).
   Google Scholar
• Datta G, White CR, Dashti N et al. Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH2. Atherosclerosis 208, 134–131 (2010).
   Google Scholar
• Goldberg DI, Nayyar, G, Garber DW et al. Sustained effects of apolipoprotein E mimetic peptides on established atherosclerotic lesions in apo E null mice. Circulation 128, A10759 (2013).
   Google Scholar
• Ason B, van der Hoorn JWA, Chan J. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J. Lipid Res. 55(11), 2370–2379 (2014).
   Google Scholar